Drug Search Results
More Filters [+]

Nebicapone

Alternative Names: nebicapone, bia 3-202
Latest Update: 2017-08-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: COMT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bial
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nebicapone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Parkinson's Disease

Phase 1: Parkinson's Disease|Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BIA-3202-202

P2

Completed

Parkinson's Disease

2007-09-21

2006-001793-24

P2

Completed

Parkinson's Disease

2007-05-31

BIA-3202-112

P1

Completed

Healthy Volunteers

2006-12-01

BIA-6512-107

P1

Completed

Parkinson's Disease

2006-10-20

Recent News Events

Date

Type

Title